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Abstract   
Summary: Protein kinase C (PKC) has been implicated in the preconditioning-induced 
cardiac protection in ischemic/reperfused myocardium. We studied the effect of PKC 
inhibition with calphostin C (25, 50, 100, 200, 400, and 800 nM), a potent and specific 
inhibitor of PKC, in isolated working nonpreconditioned and preconditioned 
ischemic/reperfused hearts. In the nonpreconditioned groups, all hearts underwent 30 min 
of nonmothermic global ischemia followed by 30 min of reperfusion. In the preconditioned 
groups, hearts were subjected to four cycles of ischemic preconditioning by using 5 min of 
ischemia followed by 10 min reperfusion, before the induction of 30 min ischemia and 
reperfusion. At low concentrations of calphostin C (25, 50, and 100 nM), the PKC inhibitor 
had no effect on the incidence of arrhythmias or postischemic cardiac function in the 
nonpreconditioned ischemic/reperfused groups. With 200 and 400 nM of calphostin C, a 
significant increase in postischemic function and a reduction in the incidence of 
arrhythmias were observed in the nonpreconditioned ischemic/reperfused groups. 
Increasing the concentration of calphostin C to 800 nM, the recovery of postischemic 
cardiac function was similar to that of the drug-free control group. In preconditioned hearts, 
lower concentrations (<100 nM) of calphostin C did not change the response of the 
myocardium to ischemia and reperfusion in comparison to the preconditioned drug-free 
myocardium. Two hundred and 400 nM of the PKC inhibitor further reduced the incidence 
of ventricular fibrillation (VF) from the preconditioned drug-free value of 50% to 0 (p < 
0.05) and 0 (p < 0.05), respectively, indicating that the combination of the two, 
preconditioning and calphostin C, affords significant additional protection. Increasing the 
concentration of calphostin C to 800 nM blocked the cardioprotective effect of 
preconditioning (100% incidence of VF). The recovery of cardiac function was similarly 
improved at calphostin C doses of 200 and 400 nM and was reduced at 800 nM (p < 0.05). 
With 200 and 400 nM of calphostin C, both cytosolic and particulate PKC activity were 
reduced by [almost equal to]40 and 60%, respectively, in both preconditioned and 
  
preconditioned/ischemic/reperfused hearts. The highest concentration of calphostin C (800 
nM) resulted in almost a complete inhibition of cytosolic (100%) and particulate (85%) 
PKC activity correlated with the abolition of preconditioning-induced cardiac protection. In 
conclusion, calphostin C protects the ischemic myocardium obtained from intact animals, 
provides significant additional protection to preconditioning at moderate doses, and blocks 
the protective effect of preconditioning at high concentrations. The dual effects of 
calphostin C appear to be strictly dose and “enzyme inhibition” related. 
 
 
 
  
Protein kinase C (PKC) was first identified by Takai et al. (1) as a proteolytically activated 
protein kinase, and is now known to be ubiquitous in many different organs. PKC is 
activated by receptor-mediated hydrolysis of inositol phospholipids, whereby it relays 
information via the cell membrane to regulate many calcium-dependent processes. PKC 
isoforms ([alpha], [beta]I, [beta]II, [gamma], [delta], [varepsilon], and [zeta]) are important 
regulators of cellular functions, including signal transduction, proliferation, and 
differentiation (2,3). Its activity is dependent on intracellular calcium and discylglycerol 
contents, both of which are regulated by phosphatidylinositol hydrolysis. In the initial phase 
of cellular responses, PKC has a dual effect, providing both positive and negative feedback 
controls over various steps of its own and other signaling pathways, including receptors 
coupled to inositol phospholipid hydrolysis and growth factors. Specific inhibitors of PKC 
may therefore have therapeutic value. Recently the activation and inhibition of PKC has 
been implicated in the mechanisms of ischemia/reperfusion-induced injury and 
preconditioning (PC) (4,5). Although staurosporine and other derivatives are potent 
inhibitors of PKC, these compounds also inhibit other protein kinases including cyclic 
adenosine monophosphate (cAMP)-dependent protein kinase (6). Calphostin C, a protein 
kinase inhibitor from Cladosporium cladosporioides, is the first specific inhibitor of PKC 
with high potency and negligible activity for other protein kinases (6). In this study, we 
tested whether the inhibition of PKC by calphostin C can reduce the incidence of 
reperfusion-induced arrhythmias and improve postischemic cardiac function. Furthermore 
we studied the effect of calphostin C in preconditioned ischemic/reperfused myocardium 
obtained from intact animals. 
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METHODS   
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Animals   
Male Sprague-Dawley rats (320-350 g body weight) were used for all studies. All animals 
received humane care in compliance with the “Principles of Laboratory Animal Care” 
formulated by the National Society for Medical Research and the “Guide for the Care and 
Use of Laboratory Animals” prepared by the National Academy of Sciences and published 
by the National Institute of Health (NIH Publication No. 86-23, revised 1985). 
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Isolated working heart preparation   
Rats were anesthetized with an intraperitoneal injection of pentobarbital sodium (60 mg/kg 
body weight) and then given intravenous heparin (500 IU/kg). After thoracotomy, the heart 
was excised and placed in ice-cold perfusion buffer. Immediately after preparation, the 
aorta was cannulated, and the heart was perfused (at 37°C) according to the Langendorff 
method for a 5-min washout period at a constant perfusion pressure equivalent to 100 cm of 
  
water (10 kPa). The perfusion medium consisted of a modified Krebs-Henseleit bicarbonate 
buffer ([millimolar concentration] sodium chloride, 118; potassium chloride, 4.7; calcium 
chloride, 1.7; sodium bicarbonate, 25; potassium biphosphate, 0.36; magnesium sulfate, 1.2; 
and glucose, 10). The Langendorff preparation was switched to the working mode after the 
washout period, as previously described in detail by Tosaki and Braquet (7) and Tosaki and 
Hellegouarch (8). Aortic flow was measured by an in-line calibrated rotameter. Coronary 
flow rate was measured by a timed collection of the coronary effluent that dripped from the 
heart. 
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Induction of ischemia and reperfusion   
After a 10-min aerobic perfusion of the heart, the left atrial inflow and aortic outflow lines 
were clamped at a point close to their origin. Reperfusion was initiated by unclamping the 
atrial inflow and aortic outflow lines. To prevent the myocardium from drying out during 
normothermic global ischemia, the thermostated glassware (in which hearts were 
suspended) was covered, and the vapor content was kept at a constant level (90-100%). 
  
Back to Top    
Experimental time course   
Ischemia and reperfusion. Hearts (n = 12 in each group) were subjected to 30 min of 
normothermic global ischemia followed by 30 min of reperfusion. Myocardial function 
(heart rate [HR], coronary flow [CF], aortic flow [AF], left ventricular pressure [LVP], and 
the first derative of LVP [LVPdp/dt]) was measured before ischemia and after 30 min of 
reperfusion. In calphostin C-treated groups, the drug (25, 50, 100, 200, 400, or 800 nM) 
was perfused for 10 min before the induction of ischemia, and pre- and postischemic 
cardiac function was recorded. 
  
Ischemic preconditioning. In the drug-free control group, four cycles of PC, each consisting 
of 5-min normothermic global ischemia followed by 10-min reperfusion, were carried out 
before the onset of 30 min of normothermic global ischemia and 30 min of reperfusion. 
Four cycles of ischemia PC were selected because by using this protocol in previous 
studies, a significant reduction in the incidence of reperfusion-induced arrhythmias was 
observed (9,10). In the drug-treated groups, calphostin C (100, 200, 400, or 800 nM) was 
perfused before the onset of PC and ischemia/reperfusion for 10 min. 
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Indices measured   
An epicardial electrocardiogram (ECG) was recorded by a polygraph throughout the 
experimental period by two silver electrodes attached directly to the heart. The ECGs were 
analyzed to determine the incidence of ventricular fibrillation (VF) and ventricular 
tachycardia (VT) and whether VF was nonsustained (spontaneously reverting to regular 
rhythm) or sustained (persisting through the first 3 min of reperfusion). After 3 min of 
sustained VF, hearts were defibrillated, and myocardial function was recorded. In additional 
experiments, preconditioned hearts were defibrillated (if it was necessary) after 15 s of 
reperfusion to avoid the fibrillation-induced stress on the myocardium, and cardiac function 
was registered. The heart was considered to be in VF if an irregular undulating baseline was 
apparent on the ECG. VT was defined as five or more consecutive premature ventricular 
complexes, and this classification included repetitive monomorphic VT, which is difficult 
to dissociate from rapid VT. In each instance, VT switched spontaneously to sinus rhythm 
or VF; therefore VT was considered nonsustained. The heart was considered to be in sinus 
rhythm if normal sinus complexes occurring in a regular rhythm were apparent on the ECG. 
Before ischemia and during reperfusion, HR, CF, and AF rates were registered. LVP and 
  
LVPdp/dt were also recorded by the insertion of a Millar catheter into the left ventricle via 
the left atrium and mitral valve. The hemodynamic parameters were registered by a Cordat 
II acquisition system. 
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Measurement of cytosolic and particulate PKC activity   
In preliminary experiments, to study the translocation of PKC to the particulate fractions, 
we directly measured the enzyme activity after four cycles of PC, each consisting of 5 min 
of ischemia followed by 10 min of reperfusion, just before the onset of 30 min of 
normothermic global ischemia in drug-free and calphostin C-treated hearts. 
  
PKC activity was also directly measured in the preconditioned ischemic/reperfused drug-
free and calphostin C-treated (200, 400, and 800 nM) ischemic/reperfused myocardium. 
Approximately 0.2 g tissue was homogenized in 2 ml of a buffer consisting of 50 mM 
Tris/HCl (pH = 7.5), 5 mM EDTA, 10 mM EGTA, 0.3% wt/vol [beta]-mercaptoethanol, 10 
mM benzamidine, and 50 mg/ml phenylmethyl-sulphonyl fluoride with a polytron 
homogenizer. The homogenate was centrifuged at 100,000 g for 60 min, and the 
supernatant was used to measure the cytosolic PKC activity. The pellet was resuspended in 
0.5 ml of homogenization buffer in the presence of 0.2% Triton X-100. After 60 min of 
incubation, the suspension was centrifuged at 100,000 g for 20 min, and the supernatant, 
fraction I, was obtained. The pellet was reextracted, recentrifuged, and additional 
supernatant was obtained (fraction II). Fractions I and II were combined and used for the 
measurement of particulate PKC activity (11,12) by using Amersham PKC assay kit. The 
substrate was Arg-Lys-Arg-Thr-Leu-Arg-Arg-Leu, which is a highly specific peptide for 
PKC. The total protein concentration in cytosolic and in particulate fractions was 
determined by using BCA (bicinchoninic acid) protein assay kit (Pierce, Rockville, IL, 
U.S.A.). PKC activity was determined in reaction mixtures (0.1 ml at 25°C) containing 12 
mM Ca-acetate in a buffer consisting of 50 mM Tris/HCl, 0.03% wt/vol Na-azide, 8 mol% 
L-[alpha]-phosphatidyl-L-serine, and 24 mg/ml phorbol 12-myristate 13-acetate in 50 mM 
Tris/HCl containing 0.05% wt/vol Na-azide (pH = 7.5), 30 mM dithiothreitol in 50 mM 
Tris/HCl, and 0.05% wt/vol Na-azide (pH = 7.4), 150 µM adenosine triphosphate (ATP), 
and 45 mM Mg-acetate in 50 mM Tris/HCl with 0.05% wt/vol sodium azide (pH = 7.5). To 
this reaction mixture, 10 µCi/ml of [[gamma]-32P]-ATP (Amresham) and 25 µg cytosolic or 
solubilized particulate protein were added. Triton X-100 was added to the supernatant 
fractions such that the concentration of Triton X-100 in both the cytosolic and particulate 
fractions was 0.04% in the final reaction mixtures. The reaction was started by adding 25 µl 
of Mg-[32P]-ATP buffer. The reaction was terminated with 100 ml of stop-reagent. Thus 
125 µl of the each terminated reaction mixture was pipetted onto a numbered square of 
binding paper, and the solution was allowed to soak into the paper. The binding paper was 
placed in 5% vol/vol acetic acid, and then the paper was carefully removed from its 
container by using suitable forceps and placed in an individual scintillation vial. Finally, 10 
ml of liquid scintillation solution was added into each vial, and the radioactivity was 
measured by a liquid scintillation counter. 
  
Back to Top    
Exclusion criteria   
Preselected exclusion criteria for our studies demanded that hearts were excluded if (a) 
ventricular arrhythmias occurred during the period before the induction of global ischemia, 
and (b) coronary flow and aortic flow were <19 ml/min and 35 ml/min, respectively, before 
the initiation of ischemia. 
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Statistics   
The data for myocardial function and cytosolic and particulate PKC activity were expressed 
as the mean ± SEM. One-way analysis of variance was first carried out to test for any 
differences between the mean values of all groups. If differences were established, the 
values of the calphostin C-treated groups were compared with those of the drug-free control 
group by a modified t test. An analog procedure was followed for distribution of discrete 
variables such as the incidence of VF and VT. An overall [chi]2 test for a 2 × n table was 
constructed, followed by a sequence of 2 × 2 [chi]2 tests to compare individual groups. A 
change of p < 0.05 was considered significant. 
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RESULTS   
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Arrhythmias in ischemic/reperfused hearts   
It has been previously reported (13) that in the rat heart, the vulnerability to reperfusion-
induced arrhythmias is determined by the duration of the preceding ischemic period and 
that a complex bell-shaped time-response relation exists. In our studies, we required that the 
control group exhibit a high vulnerability to reperfusion-induced arrhythmias to 
demonstrate any antiarrhythmic effects. To ensure this within the experimental time course 
and condition defined for this study, 30 min of normothermic global ischemia followed by 
30 min reperfusion was selected. The results demonstrate (Fig. 1A) that in rats subjected to 
ischemia/reperfusion protocol, the incidence of reperfusion-induced VF was reduced from 
its control value of 92 to 42% (p < 0.05) and 25% (p < 0.05), respectively, with the 
concentrations of 200 and 400 nM calphostin C. With a higher dose of calphostin C (800 
nM), this protection was abolished. The incidence of reperfusion-induced VT showed the 
same pattern (Fig. 1B). The loss of cardiac protection could be explained by drug toxicity or 
other nonspecific effects by using the highest concentration of calphostin C. 
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Arrhythmias in preconditioned hearts   
Hearts were subjected to four cycles of PC, each consisting of 5 min of global ischemia 
followed by 10 min of reperfusion, before the induction of 30 min of ischemia and 
reperfusion. Figure 2 shows that four cycles of PC (4 × PC) significantly reduced the 
incidence of VF (Fig. 2A) and VT (Fig. 2B) in comparison with that of the 
nonpreconditioned group. Hearts treated with calphostin C of 100, 200, or 400 nM 
demonstrated a further reduction in the incidence of arrhythmias (Fig. 2). This demonstrates 
that a combination of PC and PKC inhibition affords additional protection. At a high 
concentration (800 nM) of calphostin C, the PC-induced cardiac protection was abolished, 
indicating the importance of the concentration of PKC blocker and enzyme inhibition in our 
model system. 
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Effects of calphostin C on cardiac function in ischemic and reperfused hearts   
Table 1 shows the absolute values for HR, CF, AF, LVP, and LVPdp/dt before the 
induction of ischemia; no statistically significant difference was found between the drug-
free and calphostin-treated groups. Table 2 shows the postischemic recovery of cardiac 
function after 30 min of ischemia followed by 30 min of reperfusion in the drug-free and 
calphostin C-perfused groups. Thus in hearts perfused with 200 or 400 nM of calphostin C, 
a significant recovery in AF, LVP, and LVPdp/dt was observed in comparison with that of 
the drug-free control group. At a high concentration (800 nM), as well as at low 
  
concentrations (25, 50, or 100 nM), calphostin C failed to improve the recovery of cardiac 
function in ischemic/reperfused hearts (Table 2). 
Back to Top    
Calphostin C and cardiac function in preconditioned hearts   
Table 3 shows the absolute values for postischemic myocardial function in the drug-free 
control and drug-treated four-cycle preconditioned groups. Four cycles of PC followed by 
30 min of ischemia and 30 min of reperfusion (Table 3) resulted in a nonsignificant 
recovery of contractile function in preconditioned hearts. The perfusion of 200 and 400 nM 
calphostin C significantly improved the postischemic recovery of AF, LVP, and LVPdp/dt 
in the four-cycle preconditioned groups (Table 3). At the highest concentration of 
calphostin C (800 nM), a significant reduction in postischemic function was observed in 
preconditioned hearts (Table 3). 
  
To determine whether the duration of ventricular fibrillation (3 min) was the reason for the 
lack of PC-induced functional recovery during reperfusion, in additional studies, 
preconditioned hearts were allowed to fibrillate for only 15 s before defibrillation (if it was 
necessary) and measurements of cardiac function were done. The results show (Table 4) 
that the duration of VF may determine cardiac recovery after a period of VF, but these 
results (after 15 s or 3 min of VF) did not show a significant change in cardiac function in 
our model system. In another words, cardiac function was not significantly improved after 
four cycles of PC in hearts fibrillated for 15 s in comparison with those fibrillated for 3 min 
during the reperfusion period. These results indicate that the duration of VF <=3 min does 
not change significantly the extent of the recovery in cardiac function after four cycles of 
ischemic PC in our model. 
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Effects of calphostin C on cytosolic and particulate PKC activity   
After four PC cycles (Fig. 3), before the initiation of the 30-min ischemia and reperfusion 
protocol, cytosolic and particulate PKC activity was measured. Thus after four PC cycles, 
particulate PKC activity was significantly increased from its nonpreconditioned and 
nonischemic/reperfused value of 16 ± 2.5 pmol/min to 37 ± 4.1 pmol/min in the four-cycle 
preconditioned hearts obtained from intact animals. Cytosolic PKC activity was also 
significantly increased from its nonpreconditioned and nonischemic control value of 33 ± 5 
pmol/min to 102 ± 14 pmol/min in the four-cycle preconditioned group. Calphostin C 
reduced, in a dose-dependent manner, both the cytosolic and particulate PKC activity in the 
preconditioned myocardium (Fig. 3). 
  
In calphostin C-treated preconditioned ischemic/reperfused hearts, the activity of cytosolic 
and particulate PKC was measured after 30 min of ischemia followed by 30 min of 
reperfusion. Figure 4 shows that both cytosolic (Fig. 4A) and particulate (Fig. 4B) PKC 
activity was increased after ischemia and reperfusion in preconditioned drug-free hearts, 
and this activity was reduced by a different extent in hearts treated with various doses of 
calphostin C. Thus the activation of PKC in the preconditioned myocardium indicates the 
importance of PKC in PC, and its inhibition (%) reflected in a reduction or aggravation, 
depending on the inhibition of the enzyme or its isoforms, in the incidence of VF and VT 
(Fig. 4). It is of interest that an increase in cytosolic and particulate PKC activity was 
observed in preconditioned/ischemic/reperfused hearts and in preconditioned myocardium 
(Fig. 3). 
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DISCUSSION   
The importance of protein kinase C has recently been implicated in the mechanism of 
cardiac PC and ischemia/reperfusion-induced injury (4,5). Protein phosphorylation 
catalyzed by PKC may exert profound modulation of various Ca2+-mediated processes, such 
as release reactions and exocytosis, cell proliferation and differentiation, membrane 
conductance and transport, potentiation and desensitization of other receptor systems, 
smooth muscle contraction, and other metabolic processes (3). Different lines of evidence 
suggest that PKC modulates ion conductance by phosphorylating membrane proteins such 
as pumps, channels, and ion-exchange proteins. It has been suggested that PKC may play a 
role in Ca extrusion into the cytosol immediately after its mobilization, and that Ca-
transport ATPase is a possible target of this protein kinase. Studies with myocardial 
sarcoplasmic reticulum suggest that Ca-transport ATPase is activated by the application of 
PKC (14). 
  
In our experiments, we studied whether the specific inhibition of PKC activity by 
calphostin C would affect ischemia/reperfusion-induced injury in our model system. 
Calphostin C acts on the regulatory domain of PKC and induces a more specific inhibition 
of PKC than do other PKC inhibitors (6). Furthermore, we studied the importance of the 
enzyme inhibition in the myocardium subjected to PC. Our data show that 
ischemia/reperfusion-induced injury can be attenuated if PKC is inhibited with a selective 
antagonist (calphostin C), with reperfusion-induced arrhythmias and cardiac function used 
as end points in an in vitro rat heart preparation. The results also demonstrate that this 
protection window is within a very narrow range (200 to 400 nM) of calphostin C, where 
the inhibition of cytosolic and particulate PKC enzyme activity is between 40 and 60% in 
preconditioned and in preconditioned and ischemic/reperfused hearts. Lower concentrations 
of calphostin C (25 and 50 nM), as well as highest concentration (800 nM; cytosolic and 
particulate PKC inhibition [almost equal to]99 and 85%, respectively), failed to reduce the 
incidence of reperfusion-induced arrhythmias and improve postischemic cardiac function in 
isolated working rat heart. The reduction in the incidence of reperfusion-induced VF and 
VT was reflected in the significant improvement of postischemic cardiac function with the 
concentrations of 200 and 400 nM calphostin C. At a high concentration of calphostin C 
(800 nM), a significant reduction in postischemic cardiac function was observed in 
comparison with the drug-free ischemic/reperfused control group. 
  
It has also been proposed that PKC plays a central role in ischemic PC. It has been 
proposed that an endogenous ligand binds to the adenosine [alpha]1 receptor on the surface 
of myocytes, which then activates phospholipase C via a G protein, which then activates 
phospholipase C, causing the breakdown of phosphatidylinositol 4,5-diphosphate and 
phosphatidylcholine to produce diacylglycerol and inositol-1,4,5-trisphosphate. Increased 
concentration of diacylglycerol then activates PKC in the membrane and causes 
translocation and activation of cytosolic PKC, and the activated PKC phosphorylates a 
secondary effector, which may or may not induce the protective effect of PC (15,16). 
Evidence for the involvement of PKC is provided by Ytrehus et al. (17), who studied the 
effects of PKC inhibitors, staurosporine and polymyxin B, to block PC in a rabbit in vivo 
model in which infarct size was measured. 
  
Although PKC activation or inhibition may play an important role in preconditioned 
ischemic/reperfused hearts (4,5,15), the aforementioned studies have been carried out with 
a single dose of PKC inhibitors, without a dose-response study or measuring the inhibition 
of cytosolic or particulate PKC activity. We have found that a high concentration of the 
PKC blocker (800 nM; cytosolic and particulate enzyme inhibition was 99 and 85%) 
increased the incidence of reperfusion-induced arrhythmias and reduced the recovery of 
postischemic cardiac function in comparison with the lower concentrations of the drug. In 
  
addition, high-dose PKC blocker inhibited PC-induced cardioprotection. Surprisingly, 
lower concentrations of calphostin C (200 nM and 400 nM, enzyme inhibition 40 and 60%, 
respectively), afforded an additional protection to the precondition-mediated effect. Further 
reduction in the concentrations of calphostin C failed to reduce the incidence of arrhythmias 
and improve postischemic cardiac function. These results indicate that the inhibition of PC-
induced cardiac protection by a PKC blocker is dependent on the concentration and 
percentage inhibition of cytosolic and particulate enzyme activity. Precondition-mediated 
cardiac protection could be blocked (at high concentrations) by an inhibitor of PKC or 
could afford further protection in a dose-response manner (at low concentrations) to 
preconditioned ischemic/reperfused hearts. Our results suggest that the inhibition of enzyme 
activity at various degree by calphostin C may inhibit the function of PKC isoforms 
([alpha], [beta]I, [beta]II, [gamma], [delta], [varepsilon], and [zeta]) in various extents, and 
the inhibition of different isoforms may regulate the various phosphorylation mechanisms 
changing the function of the myocardium. Thus the inhibition of some isoforms of PKC 
may be responsible for the regulation and manifestation of arrhythmogenesis and others for 
the regulation of cardiac function or infarct size (18,19). Although PKC activity was not 
directly measured in their studies, Hu and Nattel (19) concluded, by using pharmacologic 
approaches in their PC studies, that ischemic PC in rat hearts is caused by stimulation of 
[alpha]1B-adrenoceptors by endogenous catecholamines through the activation of PKC 
through a pertussis toxin-sensitive G protein. 
The presence of different isoforms of PKC in the heart might be expected to impart a high 
degree of specificity and flexibility to the signal-transduction mechanism. Although a 
recent study reported the translocation of PKC-[zeta], the major PKC isoform, to the 
particulate fraction of ventricular myocytes by epinephrine and endothelin-1 (20), it is 
possible that different PKC isoforms could be activated selectively by different receptor 
agonists or PC. Such a mechanism could involve receptor-activated phosphatidylcholine 
hydrolysis, which is stimulated by agonists that promote phosphoinositide hydrolysis and 
results in the selective and sustained accumulation of diacylglycerol without the calcium-
mobilizing second messenger inositol-1,4,5-triphosphate (IP3). Moreover, because 
phosphoinositides and phosphatidylcholine characteristically have different fatty acyl 
moieties, phosphatidylcholine hydrolysis would be predicted to lead to the production of a 
distinct pool of diacylglycerol, which may differentially activate different isoforms of PKC 
(21). The expression of various PKC isoforms and the different numbers of PC cycles may 
be responsible for the cardiac protection observed in cardiac function, infarct size, or 
arrhythmias. PKC isoform-specific translocation to distinct intracellular structures could 
lead to differences in substrate accessibility and thereby lead to PKC isoform-specific 
actions. Thus an isoform putatively identified as PKC-[beta] has been reported to 
translocate to the sarcolemma and perinuclear area an exposure to phorbol esters, whereas a 
different and as yet unidentified PKC isoform translocates to the myofibrils under the same 
experimental conditions (22). Taken together, these studies raise the possibility that, on 
activation, distinct isoforms of PKC translocate to the distinct intracellular sites of their 
protein substrates and that isoform-dependent differences in substrate specificity and 
isoform-dependent differences in intracellular compartmentalization might determine 
functional responsiveness. 
  
Our studies provide a basis for inquiry but do not dissociate the role of different PKC 
isoforms in protein phosphorylation, as was stressed by Mitchell et al. (23), in 
preconditioned ischemic/reperfused hearts. This could be explained by the fact that PC 
under certain conditions, may attenuate the incidence of arrhythmias but may not improve 
postischemic cardiac function. Besides many positive results, PC failed to improve cardiac 
function (24,25) but reduced infarct size (24) in ischemic and reperfused hearts. These and 
  
other conflicting results may possibly be explained on the basis of experimental conditions 
including the different species and the numbers of PC cycles. Interpretation of the various 
results is further complicated by the fact that cardiac function, arrhythmias, and infarct size 
were studied as end points in many experiments, but the measurement of cytosolic and 
particulate PKC activity was not carried out with different doses of PKC inhibitors in 
preconditioned ischemic/reperfused hearts or myocytes (4,5,26). However, our studies show 
absence of additional deterioration of cardiac function after prolonged myocardial ischemia 
in the presence of previous ischemic events in the drug-free preconditioned hearts. 
Therefore it is safe to assume that brief ischemic episodes do not cause additive myocardial 
injury when isolated hearts are subjected to subsequent prolonged periods of ischemia and 
reperfusion. Our results show that arrhythmogenesis and cardiac function may be regulated 
by different isoforms of PKC (e.g., [alpha], [beta]I, [beta]II, [gamma], [delta], [varepsilon], 
and [zeta]), which may be activated or blocked at different degree in preconditioned 
ischemic/reperfused hearts, leading to cardiac protection [e.g., via the synthesis of heat-
shock proteins (27,28)] or leading to the upregulation of protooncogenes (29,30), 
aggravating the postischemic cardiac function (31,32). Immunofluorescence microscopic 
studies show (33) the translocation and activation of specific PKC isoforms in 
ischemic/preconditioned hearts via the bradykinin-mediated mechanism that (bradykinin) 
activates myocardial [beta]2-receptors to initiate a series of intracellular events leading to 
the activation of PKC and its isoforms. 
In conclusion, our results demonstrate the activation (increased particulate activity) of PKC 
in preconditioned hearts obtained from intact animals, and this increase in PC-induced PKC 
activity is sustained and can be seen after the subsequent prolonged ischemic/reperfused 
period. Furthermore, calphostin C, a PKC inhibitor, dose and “enzyme inhibition” 
dependently could block the protective effect of PC or provide significant additional 
protection to PC in ischemic/reperfused hearts. 
  
Our model has several limitations. The relaxation of cardiac muscle during normothermic 
global ischemia is independent of load and is determined primarily by the intracellular 
processes that influence the rate and extent of force inactivation, which can include the 
activation or inactivation of different enzymes including PKC isoforms, the ATP-dependent 
rate, and calcium ion sequestration capacity of the sarcoplasmic reticulum. The 
interpretation of the results must be limited by our observations in the isolated working rat 
heart and by the fact that we used an isolated preparation. The use of an isolated perfused 
heart, although permitting study of direct cardiovascular responses independent of various 
peripheral factors, has the disadvantage of being denervated and perfused with 
asanguineous solutions. The immediate extrapolation of our results, obtained in isolated rat 
hearts, to an actual clinical situation should be viewed with some caution because of the 
absence of blood and its elements (e.g., platelets and leukocytes) in our model system and 
possible interspecies differences in myocardial metabolism. 
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FIG. 1.  Dose-response studies for the ability of calphostin C to reduce 
reperfusion-induced arrhythmias. Hearts (n = 12 in each group) were 
subjected to 30-min global ischemia followed by 30-min reperfusion. 
Various concentrations of calphostin C were included in the perfusion 
buffer, and hearts were perfused with the drug before the induction 
of ischemia for 10 min. The incidence (%) of ventricular fibrillation (A) 
and ventricular tachycardia (B) is shown. Statistical comparisons have 
been made for each concentration group against the drug-free 
control group. *p < 0.05. 
FIG. 2.  The effect of calphostin C on the incidence of 
reperfusion-induced ventricular fibrillation (A) and 
ventricular tachycardia (B) in hearts subjected to four 
cycles [4 x preconditioning (PC)] of ischemic 
preconditioning before the induction of 30-min global 
ischemia followed by reperfusion. n = 12 in each group; 
+comparison was made to the nonpreconditioned (no-
PC) drug-free group (p *comparisons were made to the 
4 x PC drug-free group (p < 0.05). 
FIG. 3.  Protein kinase C inhibition measured by a direct 
radioactive method after four-cycle of preconditioning 
(PC). Hearts were subjected to 0, 200, 400, or 800 nM 
of calphostin C and four cycles of PC. Both cytosolic (A) 
and particulate (B) PKC activity were monitored. 
Comparisons were made to the PC drug-free group. C, 
Nonpreconditioned control; n = 6 in each group; mean 
+/- SEM; *p < 0.05. 
FIG. 4.  Protein kinase C inhibition measured by a direct 
radioactive method in the isolated 
preconditioned/ischemic/reperfused myocardium 
subjected to 200, 400, and 800 nM of calphostin C. 
Both cytosolic (A) and particulate (B) PKC activity were 
monitored. Comparisons were made to the 
preconditioned drug-free ischemic/reperfused hearts. 
C, Nonpreconditioned and nonischemic control; n = 6 in 
each group; mean +/- SEM; *p < 0.05. 
TABLE 1.  Effects of calphostin C on preischemic cardiac function 
TABLE 2.  Effects of calphostin C on postischemic cardiac function 
TABLE 3.  Effects of calphostin C on postischemic cardiac function in preconditioned hearts 
TABLE 4.  Effects of calphostin C on postischemic cardiac functiona in preconditioned hearts 
allowed to fibrillate for 15 S at beginning of reperfusion 
 
